Net sales and licensing income declined year-over-year, but operating losses narrowed and cash flow improved. Major licensing deals and two rights issues strengthened liquidity, supporting ongoing commercialization and R&D.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.